Insider buying last 90 days
No open-market insider purchases were filed for CLOV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CLOV insider filing, plotted on the chart in Gekko.Open CLOV in Gekko
NASDAQ: CLOV
Clover Health Investments (CLOV) Stock Analysis & Forecast
Oct 12 close
$4.78−0.01 (−0.2%)
Gekko Brief
AI summaryOct 12 closeClover Health's week centers on Medicare Advantage quality ratings, with CMS awarding its PPO MA plans a 5 Star rating and its HMO MA plan a rating for 2027. The company also confirmed it will report third-quarter 2026 financial results on 4 November 2026. Separately, an officer executed sell-to-cover transactions tied to restricted stock unit vesting, designated as mandatory tax-withholding sales rather than discretionary trades.
CLOV closed at $4.78, down 0.2%, sitting above both its 50-day average of $4.44 and 200-day average of $3.39, with the 50-day above the 200-day. The GekkoIndex reads 50.8, placing the stock in the Neutral zone, down 5.4 over the prior five readings. Price sits just 0.4% below Gekko Fair Value of $4.80, a gap within the typical 5% range. The 52-week range spans $1.58 to $5.59, and six-month returns stand at 135.5%.
The next earnings date falls on 4 November 2026, after market close, 23 days away and inside a typical 20-trading-day holding window; the prior report on 5 August 2026 beat estimates ($0.05 vs $0.04) and produced a 9.1% reaction, with an average absolute reaction of 11.7% across recent quarters. No insider, Congress, or unusual options signals appear in current windows. Seasonality from this point has averaged -2.9% over the next 20 trading days across 5 years, rising in 2 of them. Consensus among 3 analysts stands at 2 buy, 1 hold, with a $5.38 target implying 12.6% upside.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Clover Health Investments price vs fair value
Close $4.78200-day averageGekko Fair Value $4.80
Clover Health Investments quick facts
- Market cap
- $2.48B
- P/E ratio
- —
- Forward P/E
- 37.7
- EPS, TTM
- −$0.05
- Revenue, TTM
- $2.48B
- Profit margin
- -0.7%
- Dividend yield
- —
- Beta
- 2.46
- Volume
- 3.89M avg 4.64M
- 1-year return
- +79.0%
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±14.5%
- 50-day average
- $4.44
- 200-day average
- $3.39
- Next earnings
- Nov 4 after close
- Shares outstanding
- 435.4M
Clover Health Investments swing-trade checklist
Clover Health Investments scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $4.78 is above the 50-day ($4.44) and 200-day ($3.39) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
50.8, Neutral
Reading 50.8 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
0.4% below
Price is within 5% of Gekko Fair Value (0.4% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−2.9% on average
From this point in the calendar, the next 20 trading days averaged −2.9% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Clover Health Investments stock chart and price history
Clover Health Investments closed at $4.78 on Oct 12, 2026, +79.0% over the past year, inside a 52-week range of $1.58 to $5.59.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −0.8%
- 3 months
- −0.8%
- 6 months
- +135.5%
- 1 year
- +79.0%
The full CLOV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CLOV in Gekko
Follow Clover Health Investments through every session
Put CLOV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CLOV in GekkoFree for 7 days. No credit card required.
About Clover Health Investments
Clover Health Investments offers Medicare Advantage coverage to individuals who qualify for Medicare, selling both PPO and HMO health plans. The company is particularly known for its Clover Assistant, a software platform it built to support how care is delivered and managed under these plans.
Beyond writing insurance, Clover Health also carries out business activities outside the insurance side of its operations. Its core customers are Medicare-eligible individuals seeking PPO or HMO plan options, and the Clover Assistant platform underpins the way the company organizes its insurance business.
Clover Health Investments was founded in 2014 and operates from its headquarters in Franklin, Tennessee. Its shares trade on the NASDAQ under the ticker CLOV.
- Listed
- NASDAQ
- Sector
- Finance
- Industry
- Life/Health insurance
- Website
- cloverhealth.com
Clover Health Investments GekkoIndex: the smart money zone
Clover Health Investments’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.8, in the Neutral zone, down 5.4 points over five sessions.
50.8Neutral
Down 5.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | +2.7% | +12.4% | ||
| Accumulation | 240 | 0.0% | +3.5% | ||
| Neutral (current zone) | 315 | +2.8% | +7.6% | ||
| Distribution | 74 | +2.2% | +16.0% | ||
| Selling | 4 | Too few readings yet | |||
Average CLOV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CLOV price, zone by zone.Track CLOV in Gekko
Is Clover Health Investments stock overvalued? Gekko Fair Value
Clover Health Investments trades 0.4% below Gekko Fair Value of $4.80, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Clover Health Investments shares are worth, recalculated every trading day.
$4.80
Gekko Fair Value, Oct 9, 2026
0.4% below fair value · About fair value
At the end of Aug 2026 the price was 14.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open CLOV in Gekko
Clover Health Investments insider and Congress trading
No open-market insider purchases were filed for Clover Health Investments, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CLOV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CLOV, plotted on the chart in Gekko.Open CLOV in Gekko
Buybacks
Clover Health Investments has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $7.89M
- As a share of market cap
- 0.32%
- Trailing four quarters
- $30.56M
From company filings.
Clover Health Investments earnings: next date and track record
Clover Health Investments reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- $0.00
- Revenue estimate
- $740.3M
4 of 8reports beat the EPS estimate
±11.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Clover Health reported strong H1 2026 results with 48% MA membership growth and GAAP net income improvement of $67M year-over-year. Total revenue reached $1.5B (+$550M YoY), consolidated gross profit grew $104M, and operating leverage expanded 200+ basis points. The company received a 4.5-star CMS rating for payment year 2027 following a court order, and continues scaling its AI-powered Clover Assistant platform through its Counterpart Health subsidiary.
- Guidance
- Management expressed confidence in 2027 driven by continued member cohort maturation under Clover Assistant, expecting meaningful profitability expansion alongside membership growth. The 4.5-star rating provides additional flexibility to reinvest in members and extend the model to more Medicare beneficiaries.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.05 est $0.04 | $743.2M est $728.3M | +9.1% |
| May 6, 2026 | $0.07 est $0.07 | $749.2M est $714.9M | +8.0% |
| Feb 26, 2026 | −$0.10 est −$0.11 | $487.7M est $467.1M | 0.0% |
| Nov 4, 2025 | −$0.05 est $0.02 | $496.7M est $467.1M | −19.3% |
| Aug 5, 2025 | −$0.02 est −$0.01 | $477.6M est $468.3M | −21.5% |
| May 6, 2025 | $0.05 est −$0.07 | $462.3M est $466.9M | +12.5% |
| Feb 27, 2025 | −$0.05 est −$0.06 | $337.0M est $347.4M | −8.1% |
| Nov 6, 2024 | −$0.02 est −$0.01 | $331.0M est $348.0M | −15.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Clover Health Investments stock forecast and analyst price targets
Analysts’ average 12-month price target for Clover Health Investments is $5.38, +12.6% from the last close, from 3 firms rating the stock in the last 90 days.
$5.38consensus 12-month target, +12.6% from the last close
Now $4.78Avg $5.38
Low $5High $6
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 8 | Canaccord Genuity | $5.50 | +15.1% |
| Sep 10 | Deutsche Bank | $6 | +25.5% |
| Aug 6 | UBS | $5 | +4.6% |
| Aug 6 | Canaccord Genuity | $5.50 | +15.1% |
| Jul 20 | Canaccord Genuity | $5.50 | +15.1% |
+7.6%average 20-day move after past Neutral readings
−2.9%average move over the next 20 trading days in the last 5 years
±4.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Clover Health Investments seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Clover Health Investments averaged −2.9% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 3 of 5 |
| Next 10 trading days | +3.1% | 1 of 5 |
| Next 15 trading days | +5.1% | 3 of 5 |
| Next 20 trading days | −2.9% | 2 of 5 |
| Next 30 trading days | −18.0% | 0 of 5 |
For scale, CLOV’s typical 20-trading-day move in either direction is about 14.5%.
Clover Health Investments market cap and key statistics
Clover Health Investments’s market cap is $2.48B and revenue of $2.48B over the last twelve months.
Valuation
- Market cap
- $2.48B
- Forward P/E
- 37.7
- EPS, TTM
- −$0.05
- Gekko Fair Value
- $4.80
Trading
- Volume
- 3.89M
- Avg volume, 20 days
- 4.64M
- 52-week high
- $5.59
- 52-week low
- $1.58
- Shares outstanding
- 435.4M
Financials
- Revenue, TTM
- $2.48B
- Profit margin
- -0.7%
- Return on equity
- -5.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.46
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±14.5%
Clover Health Investments stock news this week
Coverage of Clover Health Investments this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.
- Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027GlobeNewsWire, Oct 8
- Under a trading plan, Jamie L. Reynoso sells Clover Health (CLOV) shares at $4.63 on average.Stock Titan, Oct 8
- At 67, He’ll Keep His Clover Medicare Advantage Plan for 2027. The Premium Will Stay $0. The Most He Can Be Billed Will Jump $1,144247 Wallst, Oct 8
- Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire, Oct 7
- An executive sells 8,750 Clover Health (CLOV) shares in a mandatory sale to cover taxes.Stock Titan, Oct 6
- An officer proposes selling 8,706 Clover Health (CLOV) shares to cover stock-award taxes.Stock Titan, Oct 6
Clover Health Investments peers
Clover Health Investments’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| PRUPrudential Financial | Accumulation | 3.1% below |
| RGAReinsurance Group of America | Distribution | 0.4% above |
| CRBGCorebridge Financial | Neutral | 4.2% below |
| EQHEquitable | Neutral | 4.8% below |
| JXNJackson Financial | Accumulation | 5.8% below |
| PRIPrimerica | Accumulation | 9.6% below |
A peer links to its own page where one exists.
Clover Health Investments stock FAQ
What is Clover Health Investments’s market cap?
Clover Health Investments’s market cap is $2.48B at the Oct 12, 2026 close of $4.78, with 435.4M shares outstanding.
What is the Clover Health Investments stock forecast?
The consensus analyst 12-month price target for Clover Health Investments is $5.38, +12.6% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Clover Health Investments stock overvalued or undervalued?
On Gekko’s estimate Clover Health Investments is about fair value: the Oct 12, 2026 close of $4.78 is 0.4% below Gekko Fair Value of $4.80. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Clover Health Investments report earnings next?
Clover Health Investments is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of $0.00 per share on revenue of $740.3M. Clover Health Investments beat the earnings estimate in 4 of its last 8 reports, moving 11.7% on average across the report.
What is Clover Health Investments’s 52-week high and low?
Clover Health Investments’s 52-week high is $5.59 and its 52-week low is $1.58; it closed at $4.78 on Oct 12, 2026, +79.0% over the past year. Over the last five years the shares peaked at $8.58 on Oct 14, 2021.
Is Clover Health Investments stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (trend), 2 as mixed (gekkoindex and fair value) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Clover Health Investments the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.